Dr Reddy's Laboratories Share Price
(DRREDDY)
₹1128.15
as on 04:01PM, 25 Feb 2025
Dr Reddy's Laboratories Performance
Day's Low
Day's High
₹1,122.5Day's Price Range₹1,169.5552 Week's Low
52 Week's High
₹1,12052-Week Price Range₹1,421.49
| Returns % | |
| 1 Month Return | -5.8 % |
| 3 Month Return | -6.66 % |
| 1 Year Return | -12.42 % |
| Market Stats | |
| Previous Close | ₹1,164.55 |
| Open | ₹1,167.15 |
| Volume | 64.63L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹94,137.81Cr |
Dr Reddy's Laboratories Key Statistics
P/E Ratio
17.49
PEG Ratio
10.73
Market Cap
₹94,137.81 Cr
P/B Ratio
4.22
EPS
66.882
Dividend Yield
0.65
Sector
Pharmaceuticals
ROE
19.42
Dr Reddy's Laboratories Mutual Fund Holdings
Dr Reddy's Laboratories Analyst Rating
based on 39 analysts
35.90%
Buy
28.21%
Hold
35.90%
Sell
Based on 39 analysts offering long term price targets for Dr Reddy's Laboratories. An average target of ₹1347.43
Source: S&P Global Market Intelligence
Dr Reddy's Laboratories Share analysis
Dr Reddy's Laboratories price forecast by 39 analysts
Upside of19.44%
High
₹1723
Target
₹1347.43
Low
₹961
Dr Reddy's Laboratories target price ₹1347.43, a slight upside of 19.44% compared to current price of ₹1128.15. According to 39 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Reddy's Laboratories revenue growth forecast
Expected growth rate Q1, FY2027:24.73%
Forecast
Actual
Including amortisation and stock based compensations
Dr Reddy's Laboratories EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Dr Reddys Laboratories Ltd
Dr. Reddys Shares Rise Amid Tariff Concerns - 24 Feb, 2025
Concerns over potential tariffs from the US could impact EBITDA for Dr. Reddys and others. However, shares of Dr. Reddys rose, contributing to Nifty Pharma's recovery.Citi Research Backs Dr. Reddys Amid Market Concerns - 21 Feb, 2025
Citi Research prefers Dr. Reddys Laboratories for its reduced exposure to the US generic drugs market, amidst concerns over potential tariffs affecting drug prices.Dr Reddy's Faces Earnings Pressure and Stock Decline - 19 Feb, 2025
Dr Reddy's Laboratories is facing potential earnings pressure due to a possible 10% duty on drug exports. The stock has seen significant trading volume and a notable decline in price, with plans for a Canada launch in 2026 that could boost sales.Dr Reddy's EPS Impact from Revlimid - 18 Feb, 2025
Dr Reddy's Laboratories is expected to face a 7% to 8% EPS cut due to Revlimid, while Sun Pharma and Cipla are less affected, with Sun Pharma being the least impacted.Dr. Reddys Faces Potential Challenges Ahead - 17 Feb, 2025
Dr. Reddys Laboratories, along with other leading pharmaceutical companies, may encounter significant challenges due to pricing pressures and margin erosion affecting US market earnings.Dr. Reddy's Secures Major Biosimilar Deal - 06 Feb, 2025
Dr. Reddy's Laboratories has entered a significant licensing agreement with Shanghai Henlius Biotech for the development and commercialization of HLX15, a biosimilar to Darzalex, with exclusive rights in the U.S. and Europe. The deal is valued at up to $131.6 million, enhancing Dr. Reddy's oncology portfolio in regulated markets.Dr. Reddy's Faces Penalty Over GST Refund Issue - 02 Feb, 2025
Dr. Reddy's Laboratories has been ordered to pay a ₹184 crore penalty for receiving an excess GST refund. The company plans to appeal the decision, stating no material impact on its operations.Union Budget and Market Impact on Dr Reddy's - 01 Feb, 2025
The Union Budget 2025-26 is seen as beneficial for the pharmaceutical sector, with potential boosts to R&D and healthcare. However, Dr Reddy's faced losses amid market fluctuations.Positive Developments for Dr. Reddy's Laboratories - 31 Jan, 2025
Dr. Reddy's Laboratories is anticipated to benefit from a Production-Linked Incentive (PLI) scheme for anti-diabetic and weight-loss medications, boosting investor sentiment.Dr Reddy's Labs Reports Q4 2024 Financials - 28 Jan, 2025
Dr Reddy's Laboratories reported consolidated net sales of Rs 8,381.20 crore for December 2024, up 15.81% YoY. Net profit increased by 2.38% to Rs 1,413.70 crore, while EBITDA rose 8.21%. However, EPS decreased significantly to Rs 16.97. The stock closed at Rs 1,197.65, reflecting a -12.45% return over the last six months.Dr Reddy's Target Price Adjusted Amid Challenges - 27 Jan, 2025
KR Choksey has reduced the target price for Dr Reddy's Laboratories to Rs 1,245, citing increased competition and pricing pressures, while maintaining a HOLD rating.
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, 1.25K Cr → 1.41K Cr (in ₹), with an average increase of 11.2% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 10.86% to 11.14% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 7.31K Cr → 8.53K Cr (in ₹), with an average increase of 5.0% per quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 9.97% to 10.22% in Dec 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 26.64% of holdings in Dec 2024 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 27.53% to 26.85% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, DRREDDY stock has moved down by -3.2%
News
Dr Reddy's Faces Challenges from Proposed US Tariffs on Pharma Exports
GV Prasad of Dr Reddy's says 25% tariff on pharma exports could make medicines costlier for US consumers. North America, which is predominantly US contributed about 46.5% of Dr Reddys overall revenues of Rs. 27,916.4 crore in FY24. Theyre talking about tariffs and I dont know what the level of tariff is, said Prasad told media on the side-lines of annual life sciences event BioAsia 2025 in Hyderabad. I think itll make it costlier for the US consumers or the US intermediaries, Prasad added. Prasad said shifting all these products (manufacturing) from worldwide into US is not practical. Firstly, they dont have that much capacity, secondly their costs are high even with the tariff, Prasad said. Prasad said Dr Reddys has manufacturing footprint in US, but its expensive to make products in the US at scale and already the pricing is quite low. I think Indian and Chinese companies will still be competitive (with tariffs), he added. Everybodys waiting and watching, Prasad added. In 2024, India exported drugs worth around $8.73 billion to the US — about 31 percent of its total pharma exports. While the Trump administration is yet to come out with finer details of the proposed tariffs, but shares of companies like Dr Reddys with huge exposure to US market have fallen by 6% in last one week. Currently, Indian companies exporting to the US face almost zero import duty. India, on the other hand, imposes about 10 percent tax on pharma imports from the US. Shares of Dr Reddys declined 3.28% on BSE to end at Rs 1126.55 apiece on Tuesday.25 Feb, 2025 08:39 PMDr. Reddy’s API Plant Receives VAI Classification from U.S. FDA
An active pharmaceutical ingredients (API) manufacturing facility of Dr. Reddys Laboratories in Hyderabad inspected last year by the United States Food and Drug Administration (U.S. FDA) has since been classified as Voluntary Action Indicated (VAI) by the agency. The U.S. FDA has classified the inspection as VAI and concluded that the inspection is closed..., the generic drugmaker on Tuesday (February 25, 2025) said in an update to the stock exchanges on the inspection of the API manufacturing facility (CTO-2) in Bollaram, Hyderabad. The U.S. FDA had conducted the GMP inspection from November 13-19 and issued a Form 483 with seven observations to the facility.25 Feb, 2025 05:56 PMUSFDA Issues Compliance Notice to Dr Reddys Laboratories
USFDA asks Dr Reddy's to sort out issues at its Hyderabad facility. The US FDA has classified the inspection as Voluntary Action Indicated (VAI) and has marked the inspection as closed. A VAI classification from the USFDA means an inspection identified certain issues; however, the FDA will not take immediate action. Instead, the facility is allowed to address and rectify these issues voluntarily. Dr Reddys Laboratories reported a 2.5% year-on-year (YoY) increase in net profit at ₹1,413.3 crore for the third quarter that ended on December 31, 2024, missing estimates. In the corresponding quarter of the previous fiscal, Dr Reddys Laboratories posted a net profit of ₹1,379 crore. The CNBC-TV18 poll had predicted a profit of ₹1,501.4 crore for the quarter under review. The companys revenue from operations increased 15.9% to ₹8,358.6 crore against ₹7,215 crore in the year-ago period. The CNBC-TV18 poll had predicted revenue of ₹8,347.85 crore for the quarter under review. At the operating level, EBITDA was up 8.9% to ₹2,298.2 crore in the third quarter of this fiscal over ₹2,111 crore in Q3 FY24. The CNBC-TV18 poll had predicted an EBITDA of ₹2,343.67 crore for the quarter under review. Shares of Dr Reddys Laboratories Ltd ended at ₹1,126.55, down by ₹38.20, or 3.28% on the BSE.25 Feb, 2025 05:33 PMDr Reddy's Laboratories Financials
Index Inclusions
Dr Reddy's Laboratories Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.64% | 0.00 | |
| Foreign Institutions | 26.85% | ||
| Mutual Funds | 11.14% | 2.57 | |
| Retail Investors | 10.22% | 2.49 | |
| Others | 25.15% | 0.64 |
Dr Reddy's Laboratories Key Indicators
Dr Reddy's Laboratories Valuation
Dr Reddy's Laboratories in the last 5 years
Lowest (3.37x)
October 27, 2019
Today (17.49x)
February 25, 2025
Industry (50.89x)
February 25, 2025
Highest (53.88x)
December 18, 2020
Dr Reddy's Laboratories Earnings and Dividends
Dr Reddys Laboratories Ltd Earnings Results
Dr Reddys Laboratories Ltd’s net profit jumped 2.38% since last year same period to ₹1,413.70Cr in the Q3 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated 12.58% jump in its net profits since last 3-months.
Read More about Earnings ResultsDr Reddys Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Dr Reddys Laboratories Ltd has declared dividend of ₹40 - translating a dividend yield of 7.09%.
Read More about Dividends
Dr Reddy's Laboratories Technicals Summary
Bearish
Neutral
Bullish
Dr Reddys Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.
Dr Reddy's Laboratories Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹94,137.81 Cr | 16.68% | 0.52 | ₹5,577 Cr | ₹28,011 Cr | |
| HOLD | ₹1,52,017.93 Cr | 33.47% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,02,579.90 Cr | 33.86% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹38,563.27 Cr | 1.5% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹26,325.68 Cr | -2.44% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Dr Reddy's Laboratories
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Share Price: ₹1128.15 per share as on 25 Feb, 2025 04:01 PM
Market Capitalisation: ₹94,137.81Cr as of today
Revenue: ₹8,358.60Cr as on December 2024 (Q4 24)
Net Profit: ₹1,404.20Cr as on December 2024 (Q4 24)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddy's Laboratories |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Dr Reddys Laboratories Ltd
What is Dr Reddys Laboratories Ltd price today?
Dr Reddys Laboratories Ltd share price today stands at ₹1128.15, Open: ₹1167.15, Previous Close: ₹1164.55, High: ₹1169.55, Low: ₹1122.5, 52 Week High: ₹1421.49, 52 Week Low: ₹1120.
How to Buy Dr Reddys Laboratories Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Dr Reddys Laboratories Ltd shares
Is Dr Reddys Laboratories Ltd listed on NSE?
Dr Reddys Laboratories Ltd is listed on NSE
Is Dr Reddys Laboratories Ltd listed on BSE?
Dr Reddys Laboratories Ltd is listed on BSE
What are today's High and Low prices of Dr Reddys Laboratories Ltd?
- Today's highest price of Dr Reddys Laboratories Ltd is ₹1169.55.
- Today's lowest price of Dr Reddys Laboratories Ltd is ₹1122.5.
What are today's traded volumes of Dr Reddys Laboratories Ltd?
Today's traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 64.63L.
What is today's market capitalisation of Dr Reddys Laboratories Ltd?
Today's market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹94137.81Cr.
What is the 52 Week High and Low Range of Dr Reddys Laboratories Ltd?
How much percentage Dr Reddys Laboratories Ltd is down from its 52 Week High?
Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1128.15. It is down -20.64% from its 52 Week High price of ₹1421.49
How much percentage Dr Reddys Laboratories Ltd is up from its 52 Week low?
Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1128.15. It is up 0.73% from its 52 Week Low price of ₹1120
What are the historical returns of Dr Reddys Laboratories Ltd?
What is the PE ratio of Dr Reddys Laboratories Ltd today?
PE Ratio of Dr Reddys Laboratories Ltd is 17.49
PE ratio = Dr Reddys Laboratories Ltd Market price per share / Dr Reddys Laboratories Ltd Earnings per share